Table 4.
Summary of virological response
Median HCV-RNA log10 FC at day 14 (end of treatment) | HCV-RNA reduction ≥1 log10 at day 14 (end of treatment) | Median HCV-RNA log10 FC at day 28 (end of follow-up) | HCV-RNA reduction ≥0.5 log10 at day 28 (end of follow-up) | HCV-RNA reduction ≥1 log10 at day 28 (end of follow-up) | |
Placebo (n = 3, pooled data) | 0.08 | 0 | 0.06 | 0 | 0 |
Erlotinib 50 mg (n = 3) | −0.03 | 0 | 0.27 | 1 | 0 |
Erlotinib 100 mg (n = 3) | −0.12 | 0 | −0.76 | 2 | 1 |
FC, fold changes; HCV, hepatitis C virus.